GBM

Adult Glioblastoma: Optimal Approaches to a Challenging Diagnosis

...rapy, both concurrently with and after completion of radiotherapy. As healthcare professionals gain a better understanding of the molecular biology of gbm and utilize targeted therapies more frequently, there is hope for improving patient outcomes. To address the need for current education on GBM,...

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid

...l Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer initiated enrollment of primary gbm patients in a Phase III multi-center clinical trial of Neuradiab. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Adminis...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

...firmation and dosimetry study in patients with recurrent glioblastoma (GBM), and enrollment exceeds the halfway mark in our Phase II trial in relapsed gbm patients. We recently presented dosimetry study data at the Society of Nuclear Medicine 2009 Annual Meeting, further confirming that Cotara specifica...

Damon Runyon Cancer Research Foundation awards $2.7M to 7 top young clinical investigators

...istinct molecular pathways. Dr. Miller aims to use comparative analyses of gbm from both humans and mouse models 1) to develop diagnostic assays to classi...for preclinical drug development, and 3) to define the molecular changes in gbm after standard-of-care therapy. The ultimate goal of the research is to in...

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program

...edicine Annual Meeting -- --Over 65 Recurrent gbm Patients in Phase I and Phase II Clinical Trials H... enrollment in the final cohort of a second Cotara gbm trial, a dose confirmation and dosimetry study, is..., 2009. More than 65 patients with recurrent gbm have received Cotara in the current and previous c...

Bradmer announces 2009 first quarter operational and financial results

...l Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer initiated enrollment of primary gbm patients in a Phase III multi-center clinical trial of Neuradiab. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Adminis...

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

... compares favorably with other published results in newly diagnosed gbm (Reardon et al.; 2008 Neuro-Oncology 10:845); and - Sourced and valid...ancer, glioblastoma multiforme. Bradmer has initiated enrollment of primary gbm patients in a Phase III multi-center clinical trial of Neuradiab. Neuradiab...

European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors

..., and for patients with malignant gliomas, such as gbm or anaplastic astrocytoma (AA), showing recurrence...e treatment of adult patients with newly diagnosed gbm concomitantly with radiotherapy and then as mainte...ry malignant brain tumors are gliomas, with AA and gbm being the most common and among the most serious t...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

...ealthcare markets. Unlike many other solid tumors, gbm tumors do not metastasize, but cause symptoms and ...as 131-I anti-tenascin monoclonal antibody 81c6. gbm tumors typically have infiltrating edges that are ...in. Tenascin is a protein over-expressed in 99% of gbm cells but absent from normal brain cells. Abo...

Studies show novel device may enhance chemotherapy treatment in brain tumors

... effects when applying both treatments together to gbm cells in culture. "The pilot study further demo...ts human pilot study for patients with later stage gbm tumors that recurred after surgery and radiation. ...ed the median overall survival rates for recurrent gbm patients relative to historical data. NovoCure i...

GBM in Medical Technology

Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival

...s to typically add only 10-12 weeks of survival in gbm patients. Since 2005, the standard of care for patients with newly diagnosed gbm has been surgery followed by a combination of radi...ments concerning future treatment of patients with gbm using DCVax(R)-Brain and future clinical trials, a...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

..., and for patients with malignant gliomas, such as gbm or anaplastic astrocytoma (AA), showing recurrence...e treatment of adult patients with newly diagnosed gbm concomitantly with radiotherapy and then as mainte...eatment of patients with malignant glioma, such as gbm or AA, showing recurrence or progression after sta...

MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma

...ith miR-451 had a Synergistic Effect in Inhibiting gbm Growth - miR-451 was First Disclosed in a Patent...erexpressing miR-451 in-vitro caused inhibition of gbm cell growth. In addition, when combining Imatinib ... a synergistic effect has been shown in inhibiting gbm cell proliferation. Imatinib (Gleevec(R)) is the...

Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain

...survival of 17.0 months, in selected patients with gbm who received the same standard of care (n = 119). ...diation therapy, there are only two treatments for gbm patients currently approved by the U.S. Food and D...s to typically add only 10-12 weeks of survival in gbm patients. As noted above, DCVax(R)-Brain is a pe...

Cytopia Commences Second Phase II Study in Brain Cancer

...ncer known as glioblastoma multiforme (GBM). The gbm clinical trial is the first Phase II efficacy stud...ospital, will be Study Chairman for the program. gbm is currently treated by surgical resection, and/or...gnosis and median survival of less than 12 months. gbm tumors are highly vascular and heavily dependent o...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

...ata showed a mean overall PFS of 17.2 months in 19 gbm patients treated with Neuradiab. Bradmer is curren...djunct therapy to the current standard of care for gbm patients. The primary endpoint of the GLASS-ART Tr...ved in any other clinical trial in newly-diagnosed gbm to our knowledge. This is compelling because of re...

Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

...0-fold higher than in other organs, and all of the gbm patients in the study cohort discussed in this pre...ty of the treatment options currently available to gbm patients. We look forward to further assessing its...ry study at U.S. brain cancer centers is enrolling gbm patients with recurrent disease. Patients in this ...

Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

.... In his current clinical protocol, T-cells are removed from a patient with gbm and modified to express the zetakine. These modified cells are infused into...d as an "off the shelf" or allogeneic cell product immediately available to gbm patients. The data presented at AACR suggest that this strategy is effectiv...

BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer

...significant need for new treatments that can offer gbm patients and their families additional hope," said...s and potentially addresses a key pathway by which gbm cells resist the effects of existing medications. ...fely potentiate the power of current therapies for gbm and improve survival in this difficult-to-treat ca...

Anti-Cancer Drug CYT997 Update

...e administered in combination with two other approved anti-cancer agents. gbm is an aggressive brain tumor commonly treated with radiotherapy, surgical r... subsequently have very poor prognoses. Experimental therapies which attack gbm blood vessels have shown promise in treating this condition and Cytopia int...

GBM in Biological News

TGen researchers discover possible way to block the spread of deadly brain tumors

...ist in TGen's Cancer and Cell Biology Division. "Our findings suggest a novel mechanism defining NHERF-1 as a 'molecular switch' that regulates the gbm tumor cell's ability to migrate or divide,'' said Dr. Kislin, the scientific paper's lead author. Dr. Berens, the paper's senior author, said the a...

UNC study: Scientists identify chemical compound that may stop deadly brain tumors

...primary GBMs have this mutation, Xiong said. Even though these two types of gbm have a similar end result, the tumor types develop in very different ways, ... effects of the IDH1 mutation and are developing a mouse model of secondary gbm that could be used to test the potential treatment. ...

Killing brain tumors from within: A 'Trojan horse' approach

...specially in view of the fact that over-expression of EGF receptors is involved in over 25 % of all types of cancers. The strategy developed to combat gbm can also be applied to other types of receptors found on cancerous cells, he added. Last year, Prof. Levitzki was named as a winner of the prest...

Scientist works to improve treatment for brain tumors

...or maximum effectiveness. "Our goal is to prolong survival in these patients ?that's what we are fighting for," he said. Currently, people with gbm have a median survival time of 12 to 14 months and a five-year survival rate of 1 percent to 5 percent. The drug's development was based on Debins...

Radiotherapy advance points way to noninvasive brain cancer treatment

...death sentence. Of the approximately 12,000 people who are diagnosed with gbm annually in the U.S., half will die within a year, and the rest within 3 ye...ues report on research into using a new radiotherapy technique for fighting gbm with the element gadolinium. The approach might some day lead to less invas...

GBM in Biological Technology

Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.

...oncerning future securities registrations or other filings with the U.S. Securities and Exchange Commission ("SEC"), future treatment of patients with gbm using DCVax(R)-Brain, and other future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform ...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

...ed the Expected Median Survival Time for Recurrent gbm Patients - TORONTO and TUSTIN, Calif., June 1...d median survival time of six months for recurrent gbm patients. Cotara is currently being tested in thi...rial and in a Phase II clinical trial in recurrent gbm patients. Cotara specifically targets cells a...

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

...ies, announced today that it is participating in a gbm (glioblastoma multiforme) Awareness Day as a co-ho...ealthcare markets. Unlike many other solid tumors, gbm tumors do not metastasize, but cause symptoms and ...as 131-I anti-tenascin monoclonal antibody 81c6. gbm tumors typically have infiltrating edges that are ...

SuperGen Reports 2008 Third Quarter Financial Results

...ng evaluated in Phase 1 trials as a single agent and in combination with chemotherapy in patients with solid tumors. A Phase 1b study in patients with gbm is planned. October 2008: The Company presented five posters at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" on ...

Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009

... ability to precisely target tumors. All of the patients in the cohort presented have already surpassed the expected median survival time for relapsed gbm patients. -- Continued to enroll and dose patients in the Phase II safety and efficacy trial and in the Phase I dosing and dosimetry trial in patien...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008

...rials have already surpassed the expected median survival time for relapsed gbm patients. -- In February 2008, Peregrine announced that patient dosing ha...re being evaluated. -- In August 2007, Peregrine announced that the first gbm brain cancer patient had been administered Cotara in a Phase II clinical tr...

Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study

...e in the body largely unaffected. The release also reported that all of the gbm patients treated to date in the Cotara Phase II safety and efficacy trial have survived past the expected median survival time for relapsed gbm patients, an early but encouraging result. The press release can be found a...

AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting

...e United States. About Glioblastoma Multiforme gbm is the most common form of primary brain tumor. It...sis.(1) There are an estimated 10,000 new cases of gbm annually in the United States, which predominantly affects adults aged 45 to 70. Current gbm treatment options include surgical resection, radi...

Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)

...ive cancers, such as prostate, renal cell carcinoma (RCC), and the deadly disease glioblastoma (GBM). Clinically relevant orthotopic models of RCC and gbm are being used and newer forms of Hsp90 antagonists are being evaluated. In collaboration with other groups, there is also interest in identifying com...

Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT

...adults and, to a much lesser extent, in children. gbm occurs annually in 20,000 to 25,000 adults in the ...f drugs developed by Lixte that are active against gbm in the test tube. Initial studies showed that two ... activity of these drugs in animal models of human gbm and description of their pharmacologic behavior an...